ABOS

0.169712.21%
LS

Laura Stoppel

Independent Director

Dr. Laura Stoppel, Ph.D., serve as Director at Nimbus Therapeutics, LLC. She is Director of Verdiva Bio Limited since October 23, 2024. She serves as Investor Director & Board Member at CellCentric Ltd since 2024. She serves as the Member of Board Director for Indapta Therapeutics Inc. since February 2022. She has been an Independent Director of Acumen Pharmaceuticals, Inc. since November 2020. Dr. Stoppel is an Independent Director of Artiva Biotherapeutics, Inc. since June 2020 and serves on the Board of Directors for Nimbus Therapeutics & Celea Therapeutics. Dr. Stoppel serves as Partner of at RA Capital Management, L.P. Dr. Stoppel served as a Principal on the Investment Team at RA Capital Management and has previously served in various roles at RA Capital since 2016. Dr. Stoppel has served as an Analyst at RA Capital Management, L.P. Dr. Stoppel served in various roles for RA Capital Management, including as a Senior Associate on the Oncology, Ophthalmology and Neurology Teams within the TechAtlas division, from October 2018 to January 2020 and as an Associate, from October 2016 to October 2018. She is a Principal at Lori Hu and Managing Director at Vertex Ventures HC. Dr. Stoppel earned her B.A. in Biology and Psychology from Harvard University and her Ph.D. in Neuroscience from the Massachusetts Institute of Technology.

Positions